BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 3011242)

  • 21. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations.
    Müller JR; Janz S; Potter M
    Cancer Res; 1995 Nov; 55(21):5012-8. PubMed ID: 7585544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenes and avian development.
    Dieterlen-Lievre F; Jaffredo T; Bachnou N; al Moustafa AE; Saule S
    Int J Dev Biol; 1990 Mar; 34(1):61-8. PubMed ID: 2168200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topological organization of the MYC/IGK locus in Burkitt's lymphoma cells assessed by nuclear halo preparations.
    Rätsch A; Joos S; Kioschis P; Lichter P
    Exp Cell Res; 2002 Feb; 273(1):12-20. PubMed ID: 11795942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line.
    Klein G
    Ciba Found Symp; 1989; 142():36-48; discussion 48-53. PubMed ID: 2545422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME; Lemieux R; Jung D
    J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
    Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
    Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogene probes in the detection of human cancer.
    Showe LC; Croce CM
    Clin Physiol Biochem; 1987; 5(3-4):227-37. PubMed ID: 3621798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.
    Vaux DL; Cory S; Adams JM
    Nature; 1988 Sep; 335(6189):440-2. PubMed ID: 3262202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogene activation and tumor suppressor gene inactivation during multistage mouse skin carcinogenesis.
    Bowden GT; Schneider B; Domann R; Kulesz-Martin M
    Cancer Res; 1994 Apr; 54(7 Suppl):1882s-1885s. PubMed ID: 8137304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
    Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
    EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
    Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
    Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast.
    Ben-Yosef T; Yanuka O; Benvenisty N
    Oncogene; 1996 Nov; 13(9):1859-66. PubMed ID: 8934531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
    Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
    Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells.
    Eick D; Polack A; Kofler E; Lenoir GM; Rickinson AB; Bornkamm GW
    Oncogene; 1990 Sep; 5(9):1397-402. PubMed ID: 2216463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations.
    Alexander WS; Bernard O; Cory S; Adams JM
    Oncogene; 1989 May; 4(5):575-81. PubMed ID: 2657573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of myc family genes during murine development.
    Zimmerman KA; Yancopoulos GD; Collum RG; Smith RK; Kohl NE; Denis KA; Nau MM; Witte ON; Toran-Allerand D; Gee CE
    Nature; 1986 Feb 27-Mar 5; 319(6056):780-3. PubMed ID: 2419762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A murine model for B-cell lymphomagenesis in immunocompromised hosts: c-myc-rearranged B-cell lines with a premalignant phenotype.
    Felsher DW; Denis KA; Weiss D; Ando DT; Braun J
    Cancer Res; 1990 Nov; 50(21):7042-9. PubMed ID: 2208171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evidence for human tumor suppressor genes.
    Stanbridge EJ
    Princess Takamatsu Symp; 1989; 20():3-13. PubMed ID: 2577336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiation-specific expression of a novel G protein-coupled receptor from Burkitt's lymphoma.
    Dobner T; Wolf I; Emrich T; Lipp M
    Eur J Immunol; 1992 Nov; 22(11):2795-9. PubMed ID: 1425907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deregulated BCL2 expression enhances growth of a human B cell line.
    Reed JC; Haldar S; Cuddy MP; Croce C; Makover D
    Oncogene; 1989 Sep; 4(9):1123-7. PubMed ID: 2789359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.